Literature DB >> 23898212

Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.

Fan Zhang1, Ying-Jie Lu, Richard Malley.   

Abstract

Vaccines are among the most effective approaches to prevent and control many infectious diseases. Because of safety and reproducibility concerns, whole-cell vaccines (WCVs), made from live or killed microorganisms and including hundreds of antigenic components, have been mostly replaced by acellular or subunit vaccines composed of well-defined, purified antigen components. The efficacy of acellular vaccines is inferior to that of WCVs, however, for two major reasons: limited antigen diversity and reduced immunogenicity, especially in a lack of activation of antigen-specific T-cell immunity, which plays an important role in protection against mucosal and intracellular pathogens. Here we present the multiple antigen-presenting system (MAPS), which enables the creation of a macromolecular complex that mimics the properties of WCVs by integrating various antigen components, including polysaccharides and proteins, in the same construct and that induces multipronged immune responses, including antibody, Th1, and Th17 responses. Using antigens from various pathogens (Streptococcus pneumoniae, Salmonella typhi, and Mycobacterium tuberculosis), we demonstrate the versatility of the MAPS system and its feasibility for the design of unique defined-structure subunit vaccines to confer comprehensive protection via multiple immune mechanisms. Moreover, MAPS can serve as a tool for structure-activity analysis of cellular immunogens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23898212      PMCID: PMC3746895          DOI: 10.1073/pnas.1307228110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  Next generation pneumococcal vaccines.

Authors:  Kristin L Moffitt; Richard Malley
Journal:  Curr Opin Immunol       Date:  2011-04-21       Impact factor: 7.486

Review 2.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

Review 3.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

Review 4.  The role of Th17 cytokines in primary mucosal immunity.

Authors:  Jay K Kolls; Shabaana A Khader
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-20       Impact factor: 7.638

Review 5.  New horizons in adjuvants for vaccine development.

Authors:  Steven G Reed; Sylvie Bertholet; Rhea N Coler; Martin Friede
Journal:  Trends Immunol       Date:  2008-12-06       Impact factor: 16.687

6.  TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function.

Authors:  Mukanthu H Nyirenda; Lara Sanvito; Peter J Darlington; Kate O'Brien; Guang-Xian Zhang; Cris S Constantinescu; Amit Bar-Or; Bruno Gran
Journal:  J Immunol       Date:  2011-07-20       Impact factor: 5.422

7.  IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice.

Authors:  John S Cho; Eric M Pietras; Nairy C Garcia; Romela Irene Ramos; David M Farzam; Holly R Monroe; Julie E Magorien; Andrew Blauvelt; Jay K Kolls; Ambrose L Cheung; Genhong Cheng; Robert L Modlin; Lloyd S Miller
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

8.  Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model.

Authors:  Melissa J Whaley; Jacquelyn S Sampson; Scott E Johnson; Gowrisankar Rajam; Annie Stinson-Parks; Patricia Holder; Erica Mauro; Sandra Romero-Steiner; George M Carlone; Edwin W Ades
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

9.  GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.

Authors:  Ying-Jie Lu; Luciana Leite; Viviane Maimoni Gonçalves; Waldely de Oliveira Dias; Celia Liberman; Fernando Fratelli; Mark Alderson; Andrea Tate; Jean-François Maisonneuve; George Robertson; Rita Graca; Sabina Sayeed; Claudette M Thompson; Porter Anderson; Richard Malley
Journal:  Vaccine       Date:  2010-09-19       Impact factor: 3.641

Review 10.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

View more
  33 in total

1.  The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design.

Authors:  Nina M van Sorge; Jason N Cole; Kirsten Kuipers; Anna Henningham; Ramy K Aziz; Ana Kasirer-Friede; Leo Lin; Evelien T M Berends; Mark R Davies; Gordon Dougan; Fan Zhang; Samira Dahesh; Laura Shaw; Jennifer Gin; Madeleine Cunningham; Joseph A Merriman; Julia Hütter; Bernd Lepenies; Suzan H M Rooijakkers; Richard Malley; Mark J Walker; Sanford J Shattil; Patrick M Schlievert; Biswa Choudhury; Victor Nizet
Journal:  Cell Host Microbe       Date:  2014-06-11       Impact factor: 21.023

Review 2.  Beyond antigens and adjuvants: formulating future vaccines.

Authors:  Tyson J Moyer; Andrew C Zmolek; Darrell J Irvine
Journal:  J Clin Invest       Date:  2016-03-01       Impact factor: 14.808

3.  Conjugate-like immunogens produced as protein capsular matrix vaccines.

Authors:  Ann Thanawastien; Robert T Cartee; Thomas J Griffin; Kevin P Killeen; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-19       Impact factor: 11.205

4.  Progress towards the development of Klebsiella vaccines.

Authors:  Myeongjin Choi; Sharon M Tennant; Raphael Simon; Alan S Cross
Journal:  Expert Rev Vaccines       Date:  2019-06-28       Impact factor: 5.217

5.  Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies.

Authors:  Taylor C Stevenson; Colette Cywes-Bentley; Tyler D Moeller; Kevin B Weyant; David Putnam; Yung-Fu Chang; Bradley D Jones; Gerald B Pier; Matthew P DeLisa
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-19       Impact factor: 11.205

6.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

7.  Identification of the Pseudomonas aeruginosa O17 and O15 O-Specific Antigen Biosynthesis Loci Reveals an ABC Transporter-Dependent Synthesis Pathway and Mechanisms of Genetic Diversity.

Authors:  Steven M Huszczynski; Youai Hao; Joseph S Lam; Cezar M Khursigara
Journal:  J Bacteriol       Date:  2020-09-08       Impact factor: 3.490

8.  Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies.

Authors:  Eun Hwa Choi; Fan Zhang; Ying-Jie Lu; Richard Malley
Journal:  Clin Vaccine Immunol       Date:  2015-12-16

9.  Flt3-L enhances trans-epithelial migration and antigen presentation of dendritic cells adoptively transferred to genital mucosa.

Authors:  Jaehyung Park; Hannah Frizzell; Hangyu Zhang; Shijie Cao; Sean M Hughes; Florian Hladik; David M Koelle; Kim A Woodrow
Journal:  J Control Release       Date:  2020-10-06       Impact factor: 11.467

10.  Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with Rhizavidin.

Authors:  Mayra M F Barbosa; Alex I Kanno; Violeta Pancakova; Viviane M Gonçalves; Richard Malley; Leonardo P Faria; Luciana C C Leite
Journal:  Mol Biotechnol       Date:  2021-06-24       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.